biostudies-literatureShroff RKidney Research UKNational Institute for Health Research (NIHR)NIH1114-1127https://www.ebi.ac.uk/biostudies/studies/S-EPMC5837664biostudies-literatureUnknown32(7)In patients with chronic kidney disease (CKD), renal synthesis of active vitamin D [1,25-dihydroxyvitamin D (1,25(OH)2D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active vitamin D analogues in children with CKD-MBD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs has developed recommendations for the use of active vitamin D therapy in children wiNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal AssociationClinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.PMC5837664RP39/2013CDF-2016-09-038KKR/Paed2017/01ICA-CDRF-2016-02-057Bacchetta JBakkaloglu SEuropean Society for Paediatric Nephrology ChronicStefanidis CJWan MAriceta GKlaus GNagler EVEdefonti ASchmitt CPCozzolino MShroff RHaffner DVande Walle JfalseClinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.In patients with chronic kidney disease (CKD), renal synthesis of active vitamin D [1,25-dihydroxyvitamin D (1,25(OH)2D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active vitamin D analogues in children with CKD-MBD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs has developed recommendations for the use of active vitamin D therapy in children wi2017-01-01T00:00:00Z2017 Jul2025-04-04T14:48:41.472Z2025-04-04T14:48:41.472ZS-EPMC58376642887397110.1093/ndt/gfx080